SCHEMBL565270

SCHEMBL565270

CC(C)CN(Cc1ccc2c(c1)OCCCO2)C(=O)CCN(C)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 7/20 0.47
HPGD P15428 3/20 0.47
GAA P10253 2/20 0.47
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
CASP3 P42574 1/20 0.43
RAB9A P51151 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
USP2 O75604 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13284752 0.87 TSHR (0.41) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL564165 0.87 PROKR2 (0.48) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL10107603 0.85 TSHR (0.53) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL565473 0.84 GAA (0.43) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL565166 0.83 RAB9A (0.45) TSHRMAPTALDH1A1HPGDGAA
SCHEMBL565214 0.80 TSHR (0.42) TSHRMAPTALDH1A1HPGDGAA
SCHEMBL565005 0.80 ALDH1A1 (0.44) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL564825 0.79 SMN1; SMN2 (0.43) TSHRMAPTALDH1A1HPGDGAA
SCHEMBL565373 0.78 TAAR1 (0.41) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL10119879 0.77 ALDH1A1 (0.45) TSHRMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
WO-2010077976-A2 PROKINETICIN RECEPTOR ANTAGONISTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR TSHR 291/4885MAPT 4388/4885MEN1 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.